NCT06387342Phase 2Recruiting

Namodenoson Treatment of Advanced Pancreatic Cancer

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-07-15Estimated

Enrollment · participants20Estimated

Source updated2025-01-31Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Pancreatic Adenocarcinoma; Pancreatic Cancer

Treatments or interventions studied

Namodenoson 25mgDrugAlso known as CF102

Primary outcomes · main study measures

Read the study measures

measure: Adverse Events; description: Assessments of adverse events (AEs) will include characterization of type, incidence, severity (graded by CTCAE v5.0), seriousness, and relationship to treatment.; timeFrame: Every 2 weeks, assessed up to 1 year; measure: Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Change from baseline; description: Eastern Cooperative Oncology Group (ECOG) Performance Status (PS), which is a scale of functioning, from 0 (normal activity) to 5 (death); timeFrame: Every 2 weeks, assessed up to 1 year

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history